The results of the final stage of AIDS vaccine testing by the vaccine company, Johnson & Johnson, have failed, eliminating the vaccine hope. Had to go back and count again to find a new experimental vaccine.
Jenson Pharmaceuticals announced that a phase 3 trial of its AIDS vaccine would have ended after the results showed that the vaccine was insufficient to prevent HIV/AIDS infection. It is the only AIDS vaccine currently making the most progress in human trials. However, scientists are confident that it is possible to produce other new vaccines.
The vaccine trial, dubbed Mozygo, began a phase 3 trial in 2019 with a total of 3,900 volunteers, both men and women. and transgender people in 50 areas of 9 countries in North America, South America and Europe: Argentina, Brazil, Italy, Mexico, Peru, Poland, Puerto Rico, Spain and the United States. Previously, many experimental vaccines had failed during tests in the last 30 years. It can be seen as the hope of an AIDS vaccine in the last three to five years. However, researchers remain hopeful. There are still options of other vaccines still in early trials that may prevent future infections.
Dr said. Anthony S. Fuzi, director of the National Institute of Infectious Diseases: The news is disappointing. But this does not mean the end of vaccine development efforts. because there are other strategic plans as well He was referring to a research study called PrEPVacc in East Africa and South Africa. An experimental trial uses a test vaccine along with anti-infection drugs. The researchers are developing effective antibodies. which can reduce the spread of the virus The new vaccine will use new vaccine production technology. Including mRNA technology to prevent HIV infection. pharmaceutical This is a challenge in developing an AIDS vaccine. Since the disease was first discovered 40 years ago, the annual number of infections worldwide is estimated at more than 1.5 million and the death toll has been more than 650,000. Globally, 40 million are infected, and 10 million do not have access to treatment.
What a rich country AIDS may not be a public health concern. Because they have access to drugs that are highly effective in preventing the infection. There are also several other treatment options, such as oral pills or bimonthly injections, that are about to be approved for use in the United States. Or there are injectable drugs used every 6 months in the final stages of the experiment, etc. This treatment is a lifelong treatment. and some people are unable to access treatment Therefore, a safe and effective vaccine is the best solution to prevent such diseases.
Jenson Pharmaceutical Co. In a statement explaining that the company, which is part of Johnson & Johnson, has published the results of the stage 3 evaluation of the vaccine trial following a review by an independent monitoring and safety committee. In conclusion, the experimental vaccine was not effective in preventing HIV infection compared to a placebo given to the volunteer group. The safety of the experimental vaccine has not yet been established. From the conclusions of the said committee. Company suspends phase 3 human trials of AIDS vaccine
“We regret this conclusion. But we remain united with communities vulnerable to the impact of HIV infection. Despite significant advances in disease prevention following a global pandemic, 1.5 million people were infected worldwide by 2021. This reinforces that we need to address global public health issues. We remain committed to developing new innovations in the treatment of AIDS. Mosaigo continues to work meticulously to develop safe and effective vaccines. And the company would like to thank everyone involved in the research and development of the vaccine trial,” said Penny Heaton, head of vaccine development. of the Jenson Company said pharmaceuticals
Conclusions from an independent data and safety monitoring committee This is in line with the results of a phase 2 trial published in August 2021 that the trial vaccine was not effective in preventing infection among teenage women in sub-Saharan Africa. from Africa But the vaccine is still safe.
However, previous research has found that an experimental HIV vaccine can create immunity that can significantly reduce the spread of the virus. This is the first discovery that such a vaccine can produce the desired effect. The study, published in the journal Science, included 48 healthy volunteers who received two doses of the vaccine and two placebo vaccines. A tangible increase was found in the first batch of immune cells. before expanding into a perfect immune system that researchers believe The findings proved the theory. that the vaccine works effectively to prevent infection it will have such behaviour
Source: The Only HIV Vaccine in Advanced Trials That Has Failed. What Now?, New York Times
www.jnj.com
https://www.usnews.com/news/health-news/articles/2022-12-02/scientists-may-be-closer-to-effective-hiv-vaccine
Photo: Getty
